Key Takeaways

  • IL-31 signals through a receptor complex on sensory neurons, directly connecting immune cell activity to the itch sensation in preclinical and clinical research models.
  • In atopic dermatitis and prurigo nodularis, Th2-skewed inflammation drives IL-31 overproduction, which in turn amplifies neuronal sensitization—a cycle documented in preclinical and early clinical studies.
  • Nemolizumab, a monoclonal antibody targeting the IL-31 receptor alpha subunit, reduced itch scores and lesion severity in clinical trials of atopic dermatitis and prurigo nodularis.
  • The skin-brain axis concept frames atopic dermatitis as a bidirectional neuroimmune problem, with peripheral sensory neurons and central itch-processing circuits both implicated in reviewed preclinical data.
  • Serine protease inhibitors derived from helminths offer a separate experimental angle on immune tolerance in allergic disease, showing rapid suppression of type-2 immune responses in animal models.

What is IL-31 and why does it cause itch in atopic dermatitis?

IL-31 is a Th2-derived cytokine that directly activates sensory neurons in atopic dermatitis skin, producing itch through a neuroimmune signaling axis rather than through histamine-dependent pathways. Antihistamines largely fail in atopic dermatitis itch, which points squarely at IL-31 as a primary driver.

IL-31 is a four-helix bundle cytokine produced predominantly by Th2 lymphocytes and, to a lesser extent, by mast cells and basophils. It signals through a heterodimeric receptor complex — IL-31 receptor A (IL-31RA) paired with oncostatin M receptor β (OSMRβ) — expressed on dorsal root ganglion neurons, keratinocytes, and immune cells (source). The neuronal expression is the mechanistic crux: IL-31 acts directly on itch-transmitting sensory fibers without requiring an intermediary inflammatory cell.

In atopic dermatitis skin, the Th2-skewed immune environment drives IL-31 production chronically. IL-31 binds IL-31RA/OSMRβ on cutaneous sensory neurons and activates JAK1/JAK2 and downstream STAT3 signaling, which lowers the activation threshold of transient receptor potential channels — particularly TRPV1 and TRPA1 — that encode itch and pain signals (source). Neurons fire more readily. Itch becomes disproportionate to the apparent stimulus. This is peripheral sensitization.

Scratching-induced skin barrier disruption releases alarmins — TSLP, IL-33, IL-25 — that amplify Th2 polarization and sustain IL-31 output, creating a self-reinforcing itch-scratch cycle (source). Chronically elevated IL-31 also promotes nerve fiber sprouting into the epidermis, increasing the density of itch-competent terminals in lesional skin.

Neuroimmune crosstalk across the skin-brain axis positions IL-31 as a convergence point between adaptive immune activation and somatosensory signaling (source). In clinical studies, serum and lesional IL-31 concentrations correlate with itch severity scores in atopic dermatitis patients, and IL-31RA expression is upregulated in lesional versus non-lesional skin — both observations consistent with IL-31 being a quantitatively significant itch mediator.

Three features make IL-31 a tractable therapeutic target: its receptor complex is relatively restricted in expression, its signaling sits upstream of the itch-scratch cycle rather than downstream, and blocking it does not require broad immunosuppression. That last point drew peptide-based biologics — specifically nemolizumab, an anti-IL-31RA monoclonal antibody — into late-stage clinical development for atopic dermatitis and prurigo nodularis.

Disclaimer: This article is for informational purposes only. Nothing here constitutes medical advice, a treatment recommendation, or guidance on dosing or administration of any compound. Consult a qualified healthcare professional for any medical concerns.

How does the skin-brain axis amplify atopic dermatitis symptoms in research models?

In atopic dermatitis research models, the skin-brain axis amplifies symptoms through a self-reinforcing neuroimmune loop in which IL-31 and itch signaling drive each other's escalation. Keratinocytes and Th2 cells release IL-31, which binds IL-31 receptor A and oncostatin M receptor β on sensory neurons, directly triggering itch without requiring histamine as an intermediary — a mechanistic distinction confirmed in preclinical and early clinical data reviewed by Szepietowski et al..

The loop does not stop at the skin surface. Chronic scratching physically disrupts the epidermal barrier, releasing damage-associated molecular patterns that recruit more Th2 cells and mast cells, which produce additional IL-31. Szepietowski et al. describe how this cycle sustains itself: itch drives scratch, scratch drives inflammation, inflammation drives itch. The axis is bidirectional because the central nervous system feeds back into skin immunity — stress-induced neuropeptide release from cutaneous nerve endings can prime mast cell degranulation independently of antigen exposure.

Structural remodeling compounds the problem. In atopic dermatitis models, persistent Th2 signaling suppresses filaggrin and loricrin expression, thinning the stratum corneum and lowering the threshold for sensory neuron activation. Bhatt et al. map how this neuroimmune pharmacology spans the skin-brain axis: sensory afferents in lesional skin show increased density and altered neuropeptide profiles, with substance P and CGRP release amplifying local mast cell and dendritic cell responses.

Three axis-level mechanisms emerge from the reviewed literature. IL-31 acts directly on dorsal root ganglion neurons in animal models, producing itch behavior that persists even after peripheral inflammation is pharmacologically suppressed, per Szepietowski et al.. Neuroimmune crosstalk at the skin surface involves neuropeptide-driven mast cell activation that is antigen-independent, meaning psychological stress alone can trigger flares through this pathway, as outlined in Bhatt et al.. Serine protease activity in the disrupted barrier degrades tight junction proteins and activates protease-activated receptor 2 on sensory neurons, a mechanism relevant to helminth-derived serine protease inhibitor research reviewed in Gazzinelli-Guimarães et al..

Central sensitization is the endpoint that makes this axis clinically consequential in research contexts. After prolonged IL-31 signaling in animal models, spinal cord neurons show lowered activation thresholds, meaning stimuli that would not normally provoke itch — light touch, temperature change — begin to do so. Bhatt et al. identify this as a target-rich zone for neuroimmune pharmacotherapy, with precision approaches increasingly aimed at interrupting the axis at multiple nodes rather than a single cytokine or receptor.

This section is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

What do clinical studies show about nemolizumab for IL-31-driven itch?

Clinical studies show that nemolizumab, a monoclonal antibody targeting the IL-31 receptor alpha subunit, produces statistically significant reductions in IL-31-driven itch in patients with atopic dermatitis and prurigo nodularis across multiple phase II and phase III trials. The effect sizes are clinically meaningful, not marginal.

PMID 42696343 reported that nemolizumab achieved rapid itch reduction—within days of the first dose in some trial arms—which aligns with its mechanism of blocking IL-31 signaling at the receptor level before downstream neuronal sensitization can propagate. Agents that work primarily through immune cell depletion typically show itch relief only after inflammatory marker normalization; nemolizumab's speed of onset differs fundamentally.

Key findings from PMID 42696343:

  • In atopic dermatitis trials, nemolizumab reduced peak pruritus numerical rating scale (NRS) scores significantly versus placebo, with some phase III arms reporting ≥4-point reductions—a threshold widely accepted as clinically meaningful.
  • In prurigo nodularis, where IL-31 signaling is particularly elevated and lesion-associated itch is notoriously refractory, nemolizumab produced both itch reduction and nodule count decreases, suggesting the cytokine drives both the sensory and structural pathology.
  • Sleep disturbance scores improved in parallel with itch scores, consistent with IL-31's documented role in nocturnal pruritus amplification through its action on small-diameter sensory neurons.

The neuroimmune framing matters. PMID 42696144 situates nemolizumab within skin-brain axis pharmacology, noting that IL-31 receptor expression on dorsal root ganglion neurons means the cytokine acts directly on the peripheral nervous system—not solely on immune cells. Blocking that receptor with nemolizumab interrupts itch signaling at a genuinely neuronal node, which explains why itch relief precedes full skin clearance in trial data.

Adverse event profiles across the reviewed trials were generally manageable, with injection-site reactions and peripheral edema appearing at low frequencies. No serious immunosuppression signals emerged at the doses studied, which is mechanistically expected given that IL-31 blockade is relatively selective compared to broader cytokine suppression strategies.

The prurigo nodolaris data are particularly striking. Nodule resolution alongside itch reduction suggests that chronic IL-31 signaling sustains the itch-scratch cycle that physically drives nodule formation—and that interrupting the cytokine signal breaks that cycle structurally, not just symptomatically.

Disclaimer: This article is for informational purposes only. Nothing here constitutes medical advice, a treatment recommendation, or guidance on dosing or administration. All findings described are from published research studies; consult a qualified healthcare professional before making any medical decisions.

How does IL-31 relate to prurigo nodularis compared with atopic dermatitis?

IL-31 drives itch in both prurigo nodularis and atopic dermatitis, but the two conditions differ substantially in how much they depend on that single cytokine and in the structural changes that IL-31 signaling leaves behind. In prurigo nodularis, IL-31 appears to be a more dominant and self-reinforcing pathological signal than in atopic dermatitis, where it operates alongside a broader Th2 cytokine milieu.

In atopic dermatitis, IL-31 is one itch mediator among several. Th2 skewing produces IL-4, IL-13, IL-33, and TSLP in parallel, and those cytokines collectively shape barrier dysfunction, IgE sensitization, and neuronal sensitization. IL-31 contributes to itch and to some degree of epidermal thinning, but the disease does not hinge on it alone. This review describes IL-31 in atopic dermatitis as acting through JAK1/JAK2-STAT3/STAT5 signaling downstream of the IL-31RA/OSMR heterodimeric receptor, with expression concentrated in lesional skin and in the dorsal root ganglia neurons that innervate it.

Prurigo nodularis presents a different picture. The nodules that define the condition are not simply inflamed skin—they are sites of profound neural remodeling. The same review documents that IL-31 in prurigo nodularis drives a cycle in which itch provokes scratching, scratching causes mechanical trauma, and that trauma amplifies local IL-31 production and further sensitizes cutaneous nerve fibers. The result is a self-sustaining itch-scratch loop with structural consequences: increased intraepidermal nerve fiber density, upregulated substance P and CGRP in lesional tissue, and hyperactivation of TRPV1 and TRPA1 channels on sensory neurons.

Three quantitative differences stand out. IL-31 serum levels and lesional mRNA expression are consistently higher in prurigo nodularis than in atopic dermatitis in clinical data reviewed by PMID 42696343. IL-31RA is overexpressed on both keratinocytes and sensory neurons in prurigo nodularis lesions, amplifying signal transduction relative to atopic dermatitis skin. The neuroimmune axis in prurigo nodularis shows greater involvement of substance P co-signaling with IL-31, a pairing that PMID 42696343 links to the chronic, treatment-resistant character of nodular itch.

The clinical consequence is that IL-31 blockade with nemolizumab—an anti-IL-31RA monoclonal—produced more pronounced itch reduction in prurigo nodularis trials than in atopic dermatitis trials, a pattern PMID 42696343 attributes to the greater relative dependence of prurigo nodularis on this single pathway. Atopic dermatitis itch, with its redundant cytokine inputs, is less fully captured by IL-31 blockade alone.

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. All findings described are from published research and should not be used to guide clinical decisions.

What other immune pathways are researchers studying alongside IL-31 in allergic disease?

Researchers studying IL-31 and itch in allergic disease are simultaneously targeting several upstream and parallel immune pathways — most prominently the Th2 cytokine network, ILC2-driven innate signaling, and helminth-derived serine protease inhibitor mechanisms that reset immune tolerance. Each operates at a distinct node in the allergic cascade, and blocking any one of them shifts the inflammatory landscape in ways that interact with IL-31 biology.

The Th2 axis remains the most studied parallel target. IL-4, IL-5, and IL-13 drive IgE class switching, eosinophil recruitment, and barrier dysfunction — all of which amplify the keratinocyte and sensory neuron environments where IL-31 signaling does its damage. This review places IL-31 squarely within that Th2 context, describing how IL-4 and IL-13 upregulate IL-31 receptor expression on dorsal root ganglion neurons, creating a feed-forward loop between cytokine milieu and itch intensity in atopic dermatitis and prurigo nodularis (in vitro and animal models).

ILC2s are getting increasing attention as an upstream amplifier. In a mouse model of allergic asthma, this preclinical study found that reducing ILC2 numbers in lung tissue attenuated type 2 airway inflammation, with downstream effects on IL-4, IL-5, and IL-13 production. ILC2s respond to epithelial alarmins — TSLP, IL-25, IL-33 — before antigen-specific T cells are even activated, placing them upstream of the Th2 cytokine surge that feeds IL-31 production.

The neuroimmune interface is a third active research front. This pharmacotherapy review maps the skin-brain axis in detail, identifying TSLP, substance P, and nerve growth factor as co-mediators of itch and neuroinflammation that operate in parallel with IL-31 at the level of sensory neurons and skin-resident immune cells (preclinical evidence). Targeting these pathways alongside IL-31 may address the neurogenic component of chronic itch that IL-31 blockade alone does not fully resolve.

Parasite-derived immune modulators represent a mechanistically distinct angle. This in vitro and preclinical work showed that a helminth serine protease inhibitor rapidly suppressed allergic inflammation by promoting immune tolerance — driving regulatory T cell activity and dampening mast cell and eosinophil responses. The speed of tolerance induction in that model was striking: enzyme inhibitory activity shifted the immune environment before adaptive responses fully consolidated, suggesting a mechanism that could complement cytokine-targeted biologics rather than duplicate them.

This section is for informational purposes only and does not constitute medical advice, dosing guidance, or clinical recommendations. All findings described are from preclinical or early research models; outcomes in humans may differ.

FAQ

What is IL-31 and itch, and how are they connected?

IL-31 is a cytokine produced mainly by Th2 T cells that binds a receptor complex expressed on sensory neurons in the skin. In atopic dermatitis research, this binding directly triggers itch signaling, making IL-31 and itch mechanistically linked rather than merely correlated.

What cells produce IL-31 in atopic dermatitis?

Th2 lymphocytes are the primary source of IL-31 in atopic dermatitis, according to the review published in the Journal of Drugs in Dermatology (PMID 42696343). Mast cells and basophils can also contribute under certain inflammatory conditions described in that review.

How does nemolizumab work against IL-31-driven itch?

Nemolizumab is a monoclonal antibody that blocks the IL-31 receptor alpha subunit, preventing IL-31 from activating sensory neurons. Clinical trial data reviewed in PMID 42696343 showed reductions in itch intensity and skin lesion area in patients with atopic dermatitis and prurigo nodularis.

What is the skin-brain axis in the context of atopic dermatitis?

The skin-brain axis describes bidirectional signaling between peripheral skin-resident immune and nerve cells and central itch-processing circuits in the brain. A 2025 review in Naunyn-Schmiedeberg's Archives of Pharmacology (PMID 42696144) outlines how disrupting this axis at multiple points is a target for neuroimmune pharmacotherapy.

Is prurigo nodularis the same disease as atopic dermatitis?

They are distinct conditions, but both show elevated IL-31 signaling and Th2 inflammation in reviewed clinical data. Prurigo nodularis features nodular skin lesions and often more severe, treatment-resistant itch than classic atopic dermatitis.

What do helminth-derived serine protease inhibitors have to do with allergic disease?

In animal models, serine protease inhibitors from parasitic helminths rapidly suppressed type-2 immune responses associated with allergy, according to a 2025 study in Virulence (PMID 42702014). Researchers propose that mimicking this enzyme inhibitory activity could be a strategy for inducing immune tolerance in allergic conditions.

Are there safety concerns with blocking the IL-31 receptor?

Clinical trial data reviewed in PMID 42696343 reported that nemolizumab was generally well tolerated, with injection-site reactions and nasopharyngitis among the most common adverse events. Long-term safety data are still accumulating, and no conclusions about individual patient risk should be drawn from review-level evidence.

Could AI tools change how neuroimmune skin diseases are treated?

The 2025 review in Naunyn-Schmiedeberg's Archives of Pharmacology (PMID 42696144) discusses AI-enabled precision approaches for identifying patient subgroups most likely to respond to skin-brain axis therapies. These applications remain in early research stages and have not yet been validated in large clinical trials.

This article is for general information and is not medical advice. Many peptides discussed are research compounds not approved for human use — talk to a licensed clinician before using any peptide product.